Why the study?
Does blood pressure lowering therapy reduce major cardiovascular events differently in younger (<65 years) versus older (≥65 years) adults?
Does blood pressure lowering therapy reduce major cardiovascular events differently in younger (<65 years) versus older (≥65 years) adults?
Answers are grounded in this paper and cite their sources.
Blood pressure lowering provides similar relative protection against major cardiovascular events in both younger and older adults, regardless of the drug class used.
OBJECTIVE: To quantify the relative risk reductions achieved with different regimens to lower blood pressure in younger and older adults. DESIGN: Meta-analyses and meta-regression analyses used to compare the effects on the primary outcome between two age groups (<65 v > or =65 years). Evidence for an interaction between age and the effects of treatment sought by fitting age as a continuous variable and estimating overall effects across trials. PRIMARY OUTCOME: total major cardiovascular events. RESULTS: 31 trials, with 190 606 participants, were included. The meta-analyses showed no clear difference between age groups in the effects of lowering blood pressure or any difference between the effects of the drug classes on major cardiovascular events (all P> or =0.24). Neither was there any significant interaction between age and treatment when age was fitted as a continuous variable (all P>0.09). The meta-regressions also showed no difference in effects between the two age groups for the outcome of major cardiovascular events (<65 v > or =65; P=0.38). CONCLUSIONS: Reduction of blood pressure produces benefits in younger (<65 years) and older (> or =65 years) adults, with no strong evidence that protection against major vascular events afforded by different drug classes varies substantially with age.
No takes yet. Share an insight, caveat, or question.
A 2008 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: